A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Top Cited Papers
- 1 October 2018
- journal article
- review article
- Published by Elsevier BV in Cell
- Vol. 175 (2), 313-326
- https://doi.org/10.1016/j.cell.2018.09.035
Abstract
No abstract availableKeywords
Funding Information
- NIH (P50 CA196530, P30 CA16359)
- United Technologies Corporation
- Instituto de Salud Carlos III
This publication has 106 references indexed in Scilit:
- A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus InfectionPLOS ONE, 2013
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaThe New England Journal of Medicine, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaThe New England Journal of Medicine, 2011
- gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced MelanomaNew England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerThe New England Journal of Medicine, 2010
- Monoclonal antibodies: versatile platforms for cancer immunotherapyNature Reviews Immunology, 2010
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010